文献速递心脏核医学肿瘤 PET/CT

精准时代:心脏淀粉样变性核医学成像的新兴、研究与辅助放射性示踪剂

An era of precision: Emerging, research, and adjunct radiotracers for nuclear imaging of cardiac amyloidosis.
PubMed 文献 · J Nucl Cardiol · 2026-05-15

心脏淀粉样变性已从未被充分认识的心衰病因转变为可治疗的蛋白质错误折叠心肌病。99mTc骨亲和闪烁显像虽常规用于ATTR无创诊断,但示踪剂不结合淀粉样蛋白,特异性、定量及疗效监测有限。靶向淀粉样蛋白或下游过程(成纤维细胞活化、炎症、去神经)的PET/SPECT示踪剂可能重塑诊断流程、表型分型、风险分层和纵向评估。

要点

  • 124Ievuzamitide是首个获FDA突破性疗法认定的淀粉样蛋白特异性PET示踪剂,已完成3期关键评估。
  • 18Fflorbetaben也处于关键3期研究中,靶向淀粉样蛋白。
  • 68GaFAPI等辅助示踪剂用于探索心肌微环境,如成纤维细胞活化。

核心结论

  • 靶向淀粉样蛋白或下游过程的PET/SPECT示踪剂可能重新定义心脏淀粉样变性的诊断算法、表型分型、风险分层和纵向评估。

研究设计与样本

  • 综述总结了新兴、研究和辅助放射性示踪剂,包括泛淀粉样蛋白肽类示踪剂124Ievuzamitide和99mTcp5+14、芪基小分子18Fflorbetaben、蛋白类示踪剂99mTcaprotinin、Aβ淀粉样蛋白示踪剂及辅助示踪剂68GaFAPI等。

主要发现

  • 124Ievuzamitide是首个获美国FDA突破性疗法认定用于心脏淀粉样变性的淀粉样蛋白特异性PET示踪剂,已完成3期关键评估。
  • 18Fflorbetaben同样处于关键3期研究中。
  • 99mTc骨亲和闪烁显像示踪剂不结合淀粉样蛋白,淀粉样蛋白特异性、定量或疗效监测反应有限。

关键数值与推荐

  • 124Ievuzamitide靶向淀粉样纤维和淀粉样蛋白相关硫酸乙酰肝素蛋白聚糖。
  • 研究聚焦的Aβ淀粉样蛋白示踪剂包括11CPiB、18Fflorbetapir、18Fflutemetamol和更新的18Fflorbetazine,并总结其在心脏淀粉样变性中的表现。

临床怎么用

  • 99mTc骨亲和闪烁显像目前常规用于ATTR无创诊断,但直接结合淀粉样蛋白的PET/SPECT示踪剂有望改善特异性、定量和疗效监测。

局限性

  • 99mTc骨亲和闪烁显像示踪剂不结合淀粉样蛋白,淀粉样蛋白特异性、定量或疗效监测反应有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Cardiac amyloidosis (CA) has rapidly transitioned from an underrecognized cause of heart failure to a treatable protein-misfolding cardiomyopathy, driven by advances in transthyretin (TTR) stabilization and gene silencing, and immunotherapy to control monoclonal light chain production. Noninvasive diagnosis of transthyretin cardiac amyloidosis (ATTR) using technetium-99m bone-avid scintigraphy is now routine, yet these tracers do not bind amyloid and offer limited amyloid specificity, quantification, or monitoring of response to therapy. Positron emission tomography (PET) and single-photon emission computed tomography (SPECT) agents that directly engage amyloid or key downstream processes (fibroblast activation, inflammation, denervation) may redefine the diagnostic algorithm, phenotyping, risk stratification, and longitudinal assessment. Among these, iodine [124I]evuzamitide (AT-01), a radioiodinated, pan-amyloid-binding peptide targeting amyloid fibrils and amyloid associated heparan sulfate proteoglycans, has emerged as the first amyloid-specific PET radiotracer to receive U.S. FDA Breakthrough Therapy designation for CA and has completed a Phase 3 pivotal evaluation. [18F]Florbetaben is similarly poised in a pivotal Phase 3 study. Herein, we summarize 1) Emerging radiotracers primed for clinical availability, including the pan-amyloid peptide tracers, [124I]evuzamitide and [99mTc]p5+14, the stilbene-based small molecule [18F]florbetaben, and the protein-based radiotracer, [99mTc]aprotinin; 2) Research-focused, Aβ amyloid radiotracers and their performance in CA ([11C]PiB; [18F]florbetapir, [18F]flutemetamol; and newer [18F]florbetazine); and 3) Adjunct radiotracers for exploring myocardial microenvironment ([68Ga]FAPI, and others), emphasizing rationale for use, opportunities, synergies, strengths, limitations, and regulatory status. Finally, we outline future research and molecular targets to elucidate the pathology and the impact of novel amyloid therapeutics as they become available.

来源:J Nucl Cardiol,查看原文。版权归原作者所有。

引用

  1. Wall JS, Martin EB. An era of precision: Emerging, research, and adjunct radiotracers for nuclear imaging of cardiac amyloidosis. J Nucl Cardiol. 2026. PMID: 42142951. doi:10.1016/j.nuclcard.2026.102726

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。